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Treating Neonatal Meningitis
Escheria coli K1 causes neonatal meningitis, an often fatal
infection of the central nervous system. Nitric oxide plays a
key role in the pathogenesis of meningitis; however, it re-
mains unclear whether it plays a pro- or antimicrobial role.
To determine the role of inducible nitrous oxide synthase
(iNOS) in meningitis, Mittal et al (Am J Pathol, 176:1292–
1305) examined the effects of E. coli K1 infection in brains of
neonatal mice. They found that E. coli K1 infection induced
iNOS and that mice deficient in iNOSwere resistant to E. coli
infection. In addition, treatment with the iNOS-specific inhib-
itor aminoguanidine cleared the pathogen and prevented
brain damage, likely via increased uptake and killing of
bacteria by macrophages. Therefore, iNOS inhibition may
provide a new therapeutic strategy for treating neonatal E.
coli–induced meningitis.
PVL Does Not Affect MRSA-Induced
Pneumonia
Community-associated methicillin-resistant Staphlococcus
aureus (CA-MRSA) causes a wide spectrum of infections,
ranging from mild skin problems to fatal invasive diseases.
The cytolytic toxin Panton-Valentine leukocidin (PVL) is a
CA-MRSA virulence factor that has been epidemiologically
associated with the development of invasive, and some-
times fatal, pneumonia in affected patients and has there-
fore become a target for new therapeutics. To explore the
role of PVL in invasive MRSA, Olsen et al (Am J Pathol,
176:1346–1354) examined both wild-type and PVL-defi-
cient MRSA in a model of CA-MRSA pneumonia. They
found no effect of PVL on virulence in MRSA-associated
pneumonia, as a PVL-mutated strain caused similar lower
respiratory tract pathology as a wild-type strain. These data
highlight the importance of context in the pathogenesis of
MRSA-associated pneumonia.
KLK4 May Contribute to the Development of
Colon Cancer
Proteases promote cancer progression both by degrading
the extracellular matrix and by signaling through protease-
activated receptors (PARs), which can induce proliferation
and motility in colon cancer cells. The physiological activa-
tors of PARs in colon cancer remain unknown. Gratio et al
(Am J Pathol, 176:1452–1461) hypothesized that kallikrien-
related peptidases (KLKs), which have been shown to func-
tion as PAR activators in vitro and in vivo, may activate PARs
in colon cancer. They found that KLK-4 was expressed in
colon adenocarcinomas but absent from normal endothelium
and that KLK-4 expression resulted in loss of PAR1 and PAR2
in a colon cancer cell line. Moreover, KLK-4–mediated cal-
cium flux was dependent on PAR-1 but not PAR-2. Taken
together, these results suggest that KLK-4 may be an endog-
enous ligand for PAR activation in colon cancer and may
therefore provide a novel therapeutic target.
ADAMTS9 Suppresses Tumor Angiogenesis
The metalloprotease ADAMTS9 is important in melanoblast
development and as a tumor suppressor in esophageal and
nasopharyngeal cancer. Mice heterozygous for ADAMTS9
develop spontaneous neovascularization, suggesting that it
may play an inhibitory role in tumor angiogenesis. Koo et al
(Am J Pathol, 176:1494–1504) found that capillary endo-
thelial cells expressed ADAMTS9 as do capillaries growing
in heterotopic tumors. Moreover, mice that lack one copy of
ADAMTS9 had a greater level of tumor neovascularization
than wild-type mice, and in vitro blocking of ADAMTS9 in
humanmicrovascular endothelial cells resulted in increased
signs of vessel formation. In contrast, overexpression of a
catalytically active, but not inactive, form of ADAMTS9 led to
the formation of fewer tube-like structures, suggesting pro-
tease function is important in angiogenesis inhibition. Indeed,
ADAMTS9 inhibits angiogenesis through a different mech-
anism that ADAMTS1. Therefore, ADAMTS9 is a novel an-
giogenesis inhibitor that is nonredundant with ADAMTS1.
Reversing Remodeling in Chronic Inflammation
Vessel remodeling plays a pathogenic role in a number of
chronic inflammatory diseases, including asthma, chronic
obstructive pulmonary disease, rheumatoid arthritis, Crohn’s
disease, and psoriasis. Reversal of such remodeling
could prevent long-term complications from these dis-
eases. Yao et al (Am J Pathol, 176:1525–1541) used
Mycoplasma pulmonis-infected mice treated with the anti-
inflammatory corticosteroid dexamethasone to examine
the reversibility of vessel remodeling. In the absence of
dexamethasone, both angiogenic and lymphangiogenic re-
modeling occurred, whereas concurrent dexamethasone
treatment prevented this remodeling. In contrast, dexa-
methasone treatment after two weeks of remodeling re-
versed blood vessel changes but not lymphangiogenesis;
it also decreased the number of lymphocytes but not
neutrophils and macrophages. Thus, lymphatic remodel-
ing may be more persistent than blood vessel remodeling
and may play a larger role in future inflammatory episodes.
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